Connor, Clark & Lunn Investment Management (CC&L)’s Carisma Therapeutics CARM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,043	Closed	-$29.6K	–	1406
2024 Q1	$29.6K	Buy	+13,043	New	+$31.3K	﹤0.01%	1494
2023 Q3	–	Sell	-14,796	Closed	-$130K	–	1378
2023 Q2	$130K	Hold	14,796	–	–	﹤0.01%	1235
2023 Q1	$45.9K	Buy	14,796 +6,921	+88%	+$65.9K	﹤0.01%	1193
2022 Q4	$96K	Buy	7,875 +737	+10%	+$7.74K	﹤0.01%	1109
2022 Q3	$61K	Buy	+7,138	New	+$97.2K	﹤0.01%	1060
2016 Q1	–	Sell	-1,275	Closed	-$77K	–	835
2015 Q4	$77K	Hold	1,275	–	–	﹤0.01%	771
2015 Q3	$61K	Buy	1,275 +120	+10%	+$7.4K	﹤0.01%	683
2015 Q2	$65K	Buy	+1,155	New	+$163K	﹤0.01%	603

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CARM Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 13,043 shares — an estimated $29.6K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CARM in Q2 2015 and held it in 8 quarters. The position peaked at $130K in Q2 2023. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 13,043 Carisma Therapeutics shares in Q2 2024, an estimated $29.6K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Carisma Therapeutics in Q2 2015 and held it in 8 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Carisma Therapeutics position peaked at $130K in Q2 2023.
53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.